NIH selects Georgia Tech to be Cell Characterization Hub
The NIH has chosen Georgia Institute of Technology to be the cell characterization platform hub for their Regenerative Medicine Innovation Project (RMIP).
(RMIP) started with $30 million from the 21st Century Cures Act to develop new therapies from adult stem cells.
The NIH identified the key obstacles and resources that would be necessary for scalable development in this field. For example, most experts would agree that it is difficult to determine precisely how certain stem cells cause positive outcomes for patients. The NIH with the FDA and other groups designed a blueprint of the requirements for this endeavor.
The Marcus Center for Therapeutic Cell Characterization and Manufacturing and the NSF Engineering Research Center for Cell Manufacturing Technologies are among the resources at Georgia Tech supporting this IDCC platform hub.
Prof. Krish Roy, director of both CMaT and the Marcus Center, and the Robert A. Milton Endowed Chair in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, articulated a key element with respect to their research:
“We’ve been working on in-depth cell characterization for clinical trials and pre-clinical projects through the Marcus Center and CMaT for several years now, so we’re very well positioned.”
We continue to see more advances in regenerative medicine as treatments. Please watch this space as the innovations move forward.
Our Editorial Note: Above is our brief summary of an article from Georgia Tech. You may need a subscription to view the article in its entirety. Contact us if you would like to learn more about regenerative medicine and how it may help patients with Covid-19 and other medical conditions.